Dr. Biao He is a molecular geneticist and senior scientist in the Thoracic Oncology Laboratory at the UCSF Helen Diller Family Comprehensive Cancer Center. Dr. He graduated from the prestigious Tsinghua University in Beijing, China with a B.S. and M.S. in Biochemistry. He later received a Ph.D. from the University of Virginia in molecular genetics. Dr. He was recruited to the Thoracic Oncology Laboratory based on his extensive knowledge of the Wnt signaling pathway and RNA interference (RNAi). He began as a postdoctoral fellow and soon advanced to the position of Assistant Research Molecular Biologist. In 2004, Dr. He joined the UCSF faculty as an Assistant Professor in the Department of Surgery. Since 2001, Dr. He has been the author of numerous peer-reviewed papers. His current research is focused on the molecular mechanisms of non-small cell lung cancer and mesothelioma. He is also developing targeted therapies against these diseases.
Dr. He has also been the recipient of numerous awards including the Hua Luogeng Memorial Fellowship, Eileen Ludwig Award for Thoracic Oncology Research, and Barbara Isackson Award for Thoracic Oncology Research.
Dr. He's current research focuses on the molecular mechanisms in tumorigenesis of lung cancer and malignant mesothelioma, and the development of targeted therapies for these cancer types. Dr. He has been a PI and co-PI of a number of research projects funded by NIH and Foundations, such as, identification and validation of novel potential therapeutic targets in lung cancer and mesothelioma; role of inflammation and epigenetic alterations in lung carcinogenesis; elucidation of novel molecular mechanisms involving Wnt and Hedgehog signal pathways in carcinogenesis; identification and validation of prognostic and predictive markers; and development of small molecule inhibitors of signaling pathways as potential leads for targeted cancer therapies.
In the two largest clinical studies ever conducted on the molecular genetics of lung cancer, an international team, led by UCSF thoracic surgeons David M. Jablons, M.D. and Michael Mann, M.D., demonstrated that a 14-gene prognostic molecular assay better predicted the likelihood of death in early-stage lung cancer patients versus conventional staging guidelines. Johannes Kratz, M.D., a former surgical resident in the Thoracic Oncology Laboratory, helped spearhead the development of the assay and was lead author of a paper published in The Lancet discussing the results. John Minna, M.D.", Max L. Thomas Distinguished Chair in Molecular Pulmonary Oncology at UT Southwestern lauded the results, stating that the assay was "head and shoulders" above the rest and ready for "prime time" clinical use.
Biao He, Ph.D., an Assistant Professor of Surgery and molecular geneticist in the Thoracic Oncology Laboratory, was awarded an NIH R01 grant to study small molecule inhibitors of Wnt-2 transcription in NSCLC. The goal of the research is to develop novel Wnt-based therapies to treat lung cancer.
Biao He, PhD was awarded a $100,000 grant from the Joan Scarangello Foundation to Conquer Lung Cancer, also known as Joan's Legacy to study Bronchioalveolar Carcinoma (BAC): Identification of Novel Wnt Signaling-Related Therapeutic Targets Against Bronchioalveolar Carcinoma.
Adding their own contributions to a rapidly advancing field, UCSF researchers - along with colleagues from Incyte Corporation and the University of Texas Southwestern Medical Center - have described new targets in lung cancer and evaluated a promising new drug candidate that halts growth signals in tumor cells grown in the lab. Their report is featured in the July issue of the scientific journal Cancer Cell.